Jeffrey Elfenbein, DO
Internal Medicine · Seaford, NYNPI 1043308695
Payments from drug & device makers
Across 887 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$2K
- Pfizer$1K
- Biohaven Pharmaceuticals, Inc.$1K
- plus $8K from 45 others
Across 1 payment — averaging $250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$250
What the payments were for
- Consulting fees$1,7869%
- Speaking & faculty fees$8854%
- Food & beverage$17,97487%
- Education$460%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,691 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 146 | $160,386 |
| EliquisApixaban | 38 | $53,282 |
| FarxigaDapagliflozin Propanediol | 30 | $43,013 |
| TrulicityDulaglutide | 33 | $36,160 |
| JardianceEmpagliflozin | 24 | $34,785 |
| MyrbetriqMirabegron | 25 | $25,303 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $23,327 |
| JanuviaSitagliptin Phosphate | 22 | $23,069 |
| EntrestoSacubitril/Valsartan | 20 | $21,878 |
| OzempicSemaglutide | 16 | $21,354 |
| XareltoRivaroxaban | 16 | $16,834 |
| LinzessLinaclotide | 11 | $13,065 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 96 | $12,993 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $12,939 |
| Metformin Hcl | 78 | $10,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,376 | $196,546179 claims |
| PfizerEliquis | $1,458 | $53,28238 claims |
| AstraZenecaFarxiga | $2,610 | $43,01330 claims |
| GSKTrelegy Ellipta, Shingrix, Arexvy | $1,886 | $37,74888 claims |
| Boehringer IngelheimJardiance | $1,506 | $34,78524 claims |
| Astellas Pharma US IncMyrbetriq | $111 | $25,30325 claims |
| MerckJanuvia | $331 | $23,06922 claims |
| NovartisEntresto | $15 | $21,87820 claims |
| Novo NordiskOzempic | $855 | $21,35416 claims |
| Johnson & JohnsonXarelto | $274 | $16,83416 claims |
| AbbVieLinzess, Synthroid | $3,745 | $15,54859 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $29 | $2,63611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Seaford
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.